YaFarm Technologies, Inc. Recaps Major Developments
19 Febbraio 2013 - 1:30PM
Marketwired
YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the
Company) has reached several important milestones since signing the
definitive agreement with The Integrative Stem Cell Institute
(ISCI). YaFarm has appointed top level management for ISCI by
announcing David Audley as CEO and Juan A. Castillo as Chairman of
the Board of Directors. Dr. Castillo is a pioneer in regenerative
medicine and has successfully treated over 250 patients using adult
stem cells, while Mr. Audley successfully managed the International
Cellular Medicine Society (ICMS) for nearly 4 years. Under Mr.
Audley's leadership, the organization grew from 7 physicians to
over 3500 members from 35 countries.
As a result of these appointments, ICSI has secured a definitive
agreement with the Hospital Galenia in Cancun, Mexico to provide
stem cell treatments at the medical center. Galenia is a state of
the art medical facility with a staff of highly trained and
globally respected medical professionals. ISCI has begun
construction of a class 10,000, ISO 7 clean room for the processing
of autologous, mesenchymal cells for point-of-care therapies. The
ISCI lab is housed in the Hospital Galenia in Cancun, Mexico. ISCI
believes that the design and construction of this category of
laboratory space within a hospital setting is critical for the
continued advancement of the field of regenerative medicine. In
addition, ISCI has launched The International Stem Cell Practice
(ISCP) to connect physicians with opportunities for education,
training and collaboration in regenerative medicine, as well as
international patients. Members of ISCP will work directly with
ISCI in providing medical oversight and care to patients
participating in clinical studies.
Last week YaFarm announced that the ISCI has submitted its
complete protocols for the treatment of chronic and degenerative
diseases to the Institutional Review Board (IRB) of the
International Cell Surgical Society (ICSS). The IRB will study
ISCI's procedures, while also reviewing the study. The studies ISCI
submitted for approval will be conducted in its medical facility at
the Hospital Galenia in Cancun, Mexico.
David Audley, CEO of the ISCI, said, "The ISCI has pioneered the
field of cell-based regenerative medicine. We are excited about the
potential for our world-class medical facility and state-of-the-art
laboratory." Mr. Audley continued, "Through the ISCP, we plan to
educate physicians about the field of regenerative medicine, while
providing opportunities at the ISCI."
YaFarm Technologies CEO Brian Hermenze stated, "The progress we
have made since signing the definitive agreement with the ICSI has
put us ahead of schedule. Now we have a seasoned and successful
management team in place, plans for a state of the art facility,
and a network of physicians who can refer patients for
procedures."
About The Integrative Stem Cell Institute
(ISCI) The Integrative Stem Cell Institute (ISCI) is a premier
provider of point-of-care, stem cell-based therapies for patients
from around the world. With a state of the art laboratory housed
within the Hospital Galenia in Cancun, Mexico, the ISCI combines
the most advanced scientific application of stem cells with second
to none medical care within the structure of adaptive clinical
trials to effective track long term outcomes and assure patient
safety. More information on the Integrative Stem Cell Institute is
available at www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, adequate financing, and
other material risks. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance, or achievements to be materially
different from the statements made herein.
Contact: The Integrative Stem Cell Institute Contact: Miranda
Abrahams Miranda@iscelli.com Investor Contact Atlanta Capital
Partners, LLC David Kugelman (866) 692-6847 info@atlcp.com
Grafico Azioni Profile Solutions (CE) (USOTC:PSIQ)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Profile Solutions (CE) (USOTC:PSIQ)
Storico
Da Giu 2023 a Giu 2024